The United States Patent and Trademark Office (USPTO) has issued patent US12582691B2, granting Lotus Biotech.com LLC exclusive rights to methods for administering Yunnan Baiyao or Xingnaojing in patients suffering from moderate-to-severe traumatic brain injury (TBI) and those undergoing craniotomy. The patent abstract details that these methods are clinically validated for improving postoperative recovery and long-term prognosis by minimizing secondary injury, oxidative damage, and neuroinflammation, and promoting functional recovery.

This patent grant signifies a new intellectual property right related to therapeutic treatments for TBI. While not a regulatory rule imposing obligations on other entities, it establishes a legal framework around specific treatment methods. Companies involved in TBI treatment, pharmaceutical development, or the use of traditional Chinese medicines like Yunnan Baiyao or Xingnaojing should be aware of this patent to avoid potential infringement. No immediate compliance actions are required for entities not involved in the patented methods, but future commercial activities related to these specific treatments would necessitate licensing or careful navigation of the patent's scope.